| Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy. | |
| | |
MedLine Citation:
|
PMID: 18536781 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sodium oxybate is the sodium salt of gamma- hydroxybutyrate, an endogenous cerebral inhibitory neurotransmitter. It is licensed in the United States for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy and in the European Union for the treatment of narcolepsy with cataplexy. Its mode of action is uncertain, but it increases 5-hydroxytryptamine turnover, interacts with opioid systems and may act as a gamma-aminobutyric acid B receptor agonist (GABA(B)). It is rapidly absorbed and eliminated, having a mean elimination half-life of 30-60 minutes. In controlled trials in narcolepsy without cataplexy, it decreased excessive daytime sleepiness and increased several quality of life domains. In combination with modafinil, it exerted an additive effect in diminishing daytime sleepiness. Both acute (four to eight weeks) and chronic (12 months) studies have demonstrated sodium oxybate's efficacy in decreasing cataplectic attack frequency. It is well tolerated with adverse event withdrawal rates of approximately 3-10% after acute and chronic administration. There is no clear evidence of a withdrawal syndrome after abrupt cessation of therapeutic doses. Sodium oxybate appears to be an effective and well-tolerated treatment for all the key symptoms of the two forms of narcolepsy. |
| | |
Authors:
|
Richard T Owen |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs of today (Barcelona, Spain : 1998) Volume: 44 ISSN: 1699-3993 ISO Abbreviation: Drugs Today Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-06-09 Completed Date: 2008-06-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160518 Medline TA: Drugs Today (Barc) Country: Spain |
Other Details:
|
Languages: eng Pagination: 197-204 Citation Subset: IM |
Affiliation:
|
Medical Information Department, Prous Science, Barcelona, Spain. journals@prous.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Anesthesia
/
adverse effects*,
pharmacokinetics,
pharmacology,
therapeutic use* Drug Interactions Humans Narcolepsy / drug therapy* Sodium Oxybate / adverse effects*, pharmacokinetics, pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Anesthesia; 502-85-2/Sodium Oxybate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstr...
Next Document: Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for c...